| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
L-Methioninamide hydrochloride targets methionyl-tRNA synthetase, an enzyme essential for protein synthesis. By inhibiting this enzyme, the compound blocks the charging of tRNA with methionine, thereby inhibiting protein synthesis. The compound's ability to reduce CDDP toxicity suggests additional mechanisms of action. Its target is bacterial methionyl-tRNA synthetase in antimicrobial applications.
|
|---|---|
| ln Vitro |
L-Methioninamide hydrochloride demonstrates in vitro inhibition of methionyl-tRNA synthetase activity. The compound shows potent inhibitory activity against the enzyme. It can reduce CDDP toxicity in cell-based assays. These activities make it valuable for research on protein synthesis, enzyme inhibition, and drug toxicity.
|
| ln Vivo |
In vivo activity of L-methioninamide hydrochloride has been suggested by its ability to reduce CDDP toxicity. The compound's inhibition of methionyl-tRNA synthetase may have implications for treating infections or cancer. Further in vivo studies are needed to fully characterize its efficacy and safety in various disease models.
|
| Enzyme Assay |
In vitro enzyme assays for L-methioninamide hydrochloride involve measuring its inhibition of methionyl-tRNA synthetase activity. The assay typically measures the charging of tRNA with methionine in the presence of the compound. The IC50 is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for L-methioninamide hydrochloride involve treating cells with varying concentrations of the compound and measuring protein synthesis inhibition using radiolabeled amino acid incorporation assays. The compound's ability to reduce CDDP toxicity is assessed by measuring cell viability in the presence of cisplatin.
|
| Animal Protocol |
In vivo animal experiments for L-methioninamide hydrochloride are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of infection, cancer, or cisplatin-induced toxicity and evaluating efficacy by measuring disease progression or toxicity markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for L-methioninamide hydrochloride are limited. As a small molecule, its absorption, distribution, metabolism, and excretion properties would influence its bioavailability. Further pharmacokinetic studies are needed to determine its systemic exposure and elimination pathways for potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for L-methioninamide hydrochloride are limited. The compound can reduce CDDP toxicity, suggesting a potential protective effect. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References |
[1]. J Lee, et al. Methionine analogues as inhibitors of methionyl-tRNA synthetase. Bioorg Med Chem Lett. 1998 Dec 15;8(24):3511-4.
|
| Additional Infomation |
L-Methioninamide hydrochloride (CAS#: 16120-92-6) is a methionine analogue and inhibitor of methionyl-tRNA synthetase. Its molecular formula is C5H13ClN2OS with a molecular weight of 184.69. The compound can reduce CDDP toxicity. It is used in research on protein synthesis, enzyme inhibition, and drug toxicity.
|
| Molecular Formula |
C5H13CLN2OS
|
|---|---|
| Molecular Weight |
184.69
|
| Exact Mass |
184.043
|
| CAS # |
16120-92-6
|
| PubChem CID |
18531008
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
351.8ºC at 760 mmHg
|
| Melting Point |
220 °C
|
| Flash Point |
166.6ºC
|
| Vapour Pressure |
2.81E-05mmHg at 25°C
|
| LogP |
1.754
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
97
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CSCC[C@H](N)C(N)=O.Cl
|
| InChi Key |
PWCBMJHINDTXGV-WCCKRBBISA-N
|
| InChi Code |
InChI=1S/C5H12N2OS.ClH/c1-9-3-2-4(6)5(7)8;/h4H,2-3,6H2,1H3,(H2,7,8);1H/t4-;/m0./s1
|
| Chemical Name |
(2S)-2-amino-4-methylsulfanylbutanamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4145 mL | 27.0724 mL | 54.1448 mL | |
| 5 mM | 1.0829 mL | 5.4145 mL | 10.8290 mL | |
| 10 mM | 0.5414 mL | 2.7072 mL | 5.4145 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
